How to improve R&D productivity: the pharmaceutical industry's grand challenge (original) (raw)

References

  1. O'Hagan, P. & Farkas, C. Bringing pharma R.&D back to health. Bain Brief [online], (2009).
  2. Lindgardt, Z., Reeves, M. & Wallenstein, J. Waking the giant: business model innovation in the drug industry. In Vivo 26, 1–6 (2008).
    Google Scholar
  3. Garnier, J. Rebuilding the R.&D engine in big pharma. Harvard Bus. Rev. 86, 68–76 (2008). A candid assessment by the former CEO of GlaxoSmithKline of the downsides of the industry's process culture.
    Google Scholar
  4. Angell, M. The Truth about Drug Companies: How They Deceive Us and What to do About It. (Random House Trade Paperbacks, New York, 2005).
    Google Scholar
  5. Chertkow, J. Trends in pharmaceutical portfolio management: strategies to maintain profitability despite adversity. Datamonitor [online] (2008).
  6. Murray, A., Berndt, E. R. & Cutler, D. M. Prescription drug spending trends in the United States: looking beyond the turning point. Health Affairs w151–w160, (2008).
  7. EvaluatePharma Alpha World Preview 2014. Evaluate Pharma report (2009).
  8. Goodman, M. Market watch: Pharma industry performance metrics: 2007–2012E. Nature Rev. Drug Discov. 7, 795 (2008).
    Article CAS Google Scholar
  9. Mathieu, M. P., ed. Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2008/2009. (Parexel International Corporation, Waltham, 2008).
    Google Scholar
  10. Pisano, G. P. Science Business: the Promise, the Reality, and the Future of Biotech. (Harvard Business School Press, Boston, 2006). An insightful retrospective on the biotech industry, and the reasons why it has not yet lived up to its promises.
    Google Scholar
  11. DiMasi, J. A. & Grabowski, H. G. The cost of biopharmaceutical R&D: Is biotech different? Manage. Decis. Econ. 28, 469–479 (2007). A contemporary assessment of the costs to discover, develop and launch new molecular entities.
    Article Google Scholar
  12. Kola, I. The state of innovation in drug development. Clin. Pharmacol. Ther. 83, 227–230 (2008).
    Article CAS Google Scholar
  13. Cohen, F. J. Macro trends in pharmaceutical innovation. Nature Rev. Drug Discov. 4, 78–84 (2005).
    Article CAS Google Scholar
  14. Lichtenberg, F. R. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001 Int. J. Health Care Finance Econ. 5, 47–43 (2005).
    Article Google Scholar
  15. Kimball, T. R., McCoy, C. E., Khoury, P. R., Daniels, S. R. & Dolan, L. M. Obesity, diabetes damage young arteries, could shorten life. News release, American Heart Association website [online] (2009).
  16. KMR Group. Pharmaceutical Benchmarking Forum [online] (2009).
  17. Booth, B. & Zemmil, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451–456 (2004). Booth and Zemmil framed the issue of productivity in the pharmaceutical industry and provide a qualitative discussion of some of the drivers and potential solutions.
    Article CAS Google Scholar
  18. Hu, M., Schultz, K., Sheu, J. & Tschopp, D. The innovation gap in pharmaceutical drug discovery & new models for R&D success. [online], (2007).
  19. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004). This article provides an in-depth analysis of attrition by phase and therapy area, and offers a scientific approach to reduce Phase II and Phase III attrition rates.
    Article CAS Google Scholar
  20. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products[online], (2004). A seminal paper on the hurdles that must be overcome to reverse the decline in R&D productivity.
  21. Peck, R. W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today 12, 289–294 (2007).
    Article CAS Google Scholar
  22. Little, J. D. C. A proof of the queuing formula L = λ W. Oper. Res. 9, 383–387 (1961).
    Article Google Scholar
  23. Bunch, P. R. & Schacht, A. L. Modeling resource requirements for pharmaceutical R.&D. Res. Technol. Manage. 45, 48–56 (2002).
    Article Google Scholar
  24. Deloitte Touche Tohmatsu. Threading the talent needle: what global executives are saying about people and work. [online], (2009).
  25. PricewaterhouseCoopers. The changing dynamics of pharma outsourcing in Asia: are you readjusting your sights? [online], (2008).
  26. Danzon, P. M., Nicholson S. & Pereira N. S. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. J. Health Econ. 24, 317–339 (2005).
    Article Google Scholar
  27. Gregson, N., Sparrowhawk, K., Mauskopf, J. & Paul, J. Pricing medicines: theory and practice, challenges and opportunities. Nature Rev. Drug Discov. 4, 121–130 (2005).
    Article CAS Google Scholar
  28. Woodcock, J. The prospects for “personalized medicine” in drug development and drug therapy. Clin. Pharmacol. Ther. 1, 164–169 (2007).
    Article Google Scholar
  29. DiMasi, J. A. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20, 1–10 (2002).
    Article Google Scholar
  30. Pyzdek, T. The Six Sigma Handbook: The complete guide for greenbelts, blackbelts, and managers of all levels. 2nd revised edition (McGraw-Hill, New York, 2003).
    Google Scholar
  31. Goldratt, E. M. & Cox J. The goal: a process of ongoing improvement. Third edition. (Gower Publishing, Aldershot, 2004).
    Google Scholar
  32. Maca, J., Bhattacharya, S., Dragalin, V, Gallo, P, Krams, M. Adaptive seamless phase II/III designs—background, operational aspects, and examples. Drug Inf. J. 4, 463–473 (2006).
    Article Google Scholar
  33. Kramer, J. A., Sagart, J. E. & Morris, D. L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nature Rev. Drug Discov. 6, 636–649 (2007).
    Article CAS Google Scholar
  34. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).
    Article CAS Google Scholar
  35. Grenet, O. Significance of the human genome sequence to drug discovery. Pharmacogenomics J. 1, 11–12 (2001).
    Article CAS Google Scholar
  36. Horton, J. D., Cohen, J. C. & Hobbs, H. H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. S172–S177 (2009).
  37. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genet. 34, 154–156 (2003).
    Article CAS Google Scholar
  38. Cohen, J. C., Boerwinkle, E., Mosley, Jr., T. H. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
    Article CAS Google Scholar
  39. Cao, G., Qian, Y. W., Kowala, M. C. & Konrad, R. J. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocrine, Metabolic & Immune Disorders – Drug Targets. 8, 238–243 (2008).
    Article CAS Google Scholar
  40. Chan, J.C. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA 106, 9820–9825 (2009).
    Article CAS Google Scholar
  41. Shepherd, J. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care 29, 1220–1226 (2006).
    Article CAS Google Scholar
  42. Drenth, J. P. H. & Waxman, S. G. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117, 3603–3609 (2007).
    Article CAS Google Scholar
  43. Krafte, D. S. & Bannon, A. W. Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol. 8, 50–56 (2008).
    Article CAS Google Scholar
  44. Bonabeau, E. N., Bodick, N. & Armstrong, R. W. A more rational approach to new-product development. Harvard Bus. Rev. 86, 96–102 (2008). A review of Eli Lilly's Chorus model of early drug development and FIPNet strategy.
    Google Scholar
  45. Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Invest. 116, 2837–2842 (2006). A frank analysis by one of the most successful R&D leaders of problems that have fostered the current innovation crisis.
    Article CAS Google Scholar

Download references